iBio’s Protein Expression Technology Granted Two European Patent Allowances

iBioPlant-based biotechnology company iBio, specializing in developing and manufacturing biological products, was recently granted notices of intention for two European patent applications claiming novel protein expression technologies. iBio is also currently developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, among other fibrotic diseases using its iBioLaunch platform.

Entitled “Systems and Methods for Clonal Expression in Plants,” the first of the two newly patient applications involves a transgenic hairy root cell generating system, which includes a viral vector expressing a gene of interest. The company expects the system to be useful to create clonal root lines, clonal root cell lines, clonal plant cell lines, or clonal plants, with a self-replicating, episomal, extrachromosomal viral RNA vector that carries a polynucleotide of interest.

“The protein expression technologies covered by this patent have particular utility for companies interested in producing proteins in plant cell culture,” explained iBio’s vice president of intellectual property, Wayne P. Fitzmaurice, Ph.D. “Current strategies for expression of proteins in plants typically use whole plants grown in controlled environmental chambers or plant cell culture in a bioreactor. iBio has multiple proprietary systems enabling us and our clients to select the most efficient technology for a specific biopharmaceutical depending on its characteristics and commercial applications.”

The other allowed patent application involves the company’s “System for Expression of Genes in Plants,” which is a system that uses methods of expressing one or more polynucleotides of interest with resources to a set of plant viral vectors that work together. Polynucleotides of interest include encoding therapeutic proteins, antibody chains, nutritionally relevant proteins, and polynucleotides that provide a template for transcription of an active RNA species, among others.

“These allowances are important additions to our broad patent coverage of innovative technologies for development and production of biopharmaceuticals,” said the president of iBio, Robert Erwin. “Our iBioLaunch platform technology is well suited for vaccines, antibodies and other therapeutic proteins. We expect increasing commercial interest in its numerous applications, in particular, our proprietary fibrosis product, and prevention and treatment of infectious disease outbreaks.”

The applications are part of the research performed by iBio’s scientists in collaboration with the technology collaborator, the Fraunhofer USA Center for Molecular Biotechnology.

Leave a Comment

Your email address will not be published. Required fields are marked *